Concomitant brain radiotherapy and vinorelbine-ifosfamide-cisplatin chemotherapy in brain metastases of non-small cell lung cancer

Lung Cancer

Volumn 26, Issue 1, 1999, Pages 35-39

  Quantin, Xavier ^a   Khial, Farid ^a   Reme Saumon, Monique ^b   Michel, François Bernard ^a   Pujol, Jean Louis ^a  

^a HÔPITAL ARNAUD DE VILLENEUVE   (France)

^b CENTRE VAL D AURELLE   (France)

Author keywords

Brain metastasis; Cisplatin; Concomitant chemo radiotherapy; Ifosfamide; Non small cell lung cancer; Vinorelbine

Indexed keywords

CISPLATIN; IFOSFAMIDE; MESNA; NAVELBINE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN METASTASIS; BRAIN RADIATION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEASIBILITY STUDY; FEMALE; FEVER; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MULTIMODALITY CANCER THERAPY; NEPHROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMBINED MODALITY THERAPY; FEASIBILITY STUDIES; FEMALE; HUMANS; IFOSFAMIDE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; SURVIVAL RATE; TREATMENT OUTCOME; VINBLASTINE;

EID: 0033214778     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(99)00071-9     Document Type: Article

References (14)

1. Posner J.B. Management of brain metastases. Rev. Neurol. 148:1992;477-487.
2. Horton J., Baxter D.H., Olsion K.B. The management of brain metastases to the brain by irradiation and corticosteroïds. Am. J. Roentgenol. Radium Ther. Nucl. Med. 3:1971;334-335.
3. Ushio Y., Arita N., Hayakawa T., Mogami H., Hasegawa H., Bittoh S., Oku Y., Ikeda H., Kanai N., Kanoh M. Chemotherapy of brain metastases from lung cancer carcinoma: a controlled randomized study. Neurosurgery. 28:1991;201-205.
4. Quantin X., Pujol J.L., Paris A., Reme-Saumon M., Khial F., Godard P., Michel F.B. Concomitant brain radiotherapy and high-dose ifosfamide in brain relapses of lung cancer. Ann. Oncol. 8:1997;911-913.
5. World Health Organization. OMS handbook for Reporting the Results of Cancer Treatment. OMS Offset Publication No. 48. Geneva: World Health Organization, 1979.
6. Côté R., Battista R.N., Wolfson C. The Canadian neurological scale: validation and reliability assessment. Neurology. 39:1989;638-643.
7. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53:1958;457-481.
8. Hryniuk W., Goodyear M. The calculation of received dose intensity. J. Clin. Oncol. 8:1990;1935-1937.
9. Lilenbaum R.C., Langenberg P., Dickersin K. Single agent versus combination chemotherapy in patients with advanced non-small cell lung carcinoma. A meta-analysis of response toxicity and survival. Cancer. 82:1998;116-126.
10. Le Chevalier T., Brisgand D., Douillard J.Y., Pujol J.L., Alberola V., Monnier A., Riviere A., Lianes P., Chomy P., Cigolari S. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer: results of a European multicenter trial including 612 patients. J. Clin. Oncol. 12:1994;360-367.
11. Souquet P.J., Fournel P., Bohas C.H., Fortune I.C., Chatte G. Cisplatin and Ifosfamide with various doses of vinorelbine (Navelbine) in advanced non-small cell lung cancer. Semin. Oncol. 23:1996;S8-S10.
12. Baldini E., Tibaldi C., Chella A., Angeletti C.A., Silvano G., Andrei A., Algeri R., Conte P.F. Combination chemotherapy with vinorelbine, ifosfamide and cisplatin: a phase II study in stage IIIB-IV non-small cell lung cancer. Semin. Oncol. 21:1994;12-15.
13. Rey F., Astoul P., Marqueste L., Petite J.M., Boutin C., Viallat J.R. Cisplatin, ifosfamide, and vinorelbine combination chemotherapy in stage III-IV non-small-cell lung cancer: a phase II study. Am. J. Clin. Oncol. 21:1998;518-522.
14. Baldini E., Tibaldi C., Ardizzoni A., Salvati F., Antilli A., Portalone L., Barbera S., Romano F., De Marinis F., Migliorino M.R., Noseda M.A., Borghini U., Crippa M., Ferrara G., Raimondi M., Fioretti M., Bandera M., Pennucci M.C., Galeasso G., Cacciani G.C., Lepidini G., Sunseri G., Lanfranco C., Rinaldi M., Rosso R. Cisplatin-vindesine-mitomycin (MVP) vs cisplatin-ifosfamide-vinorelbine (PIN) vs carboplatin-vinorelbine (CaN) in patients with advanced non-small-cell lung cancer (NSCLC): a FONICAP randomized phase II study. Br. J. Cancer. 77:1998;2367-2370.